Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 31 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in BLO.CN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BLO.CN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Mlait (Ravinder)Director of Issuer | Acquisition in the public market at price 0.21 per share. | 20K | $4.28K |
| Feb 23, 2026 | Mlait (Ravinder)Director of Issuer | Acquisition under a prospectus exemption at price 0.36 per share. | 126K | $45.99K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.7 | -5.1 | 17.9 | 9.1 | -11.1 | -18.8 | -1.9 | -6.9 | -21.1 | -20.0 | −48.3% | ||
| 2025 | 75.0 | -22.3 | 24.1 | 11.1 | 0.0 | 5.0 | -6.3 | -1.7 | 3.4 | -11.7 | -5.7 | 16.0 | +81.2% |
| 2024 | 19.4 | 0.0 | 2.3 | 86.4 | 85.4 | -39.5 | 15.2 | -11.3 | 0.0 | -10.6 | -4.8 | -20.0 | +77.8% |
| 2023 | 24.6 | -1.2 | -10.0 | -12.5 | -4.8 | -11.7 | -1.9 | -3.8 | 12.0 | -17.9 | -6.5 | -16.3 | −44.6% |
| 2022 | 14.8 | 0.0 | 0.0 | -12.9 | -3.7 | -15.4 | -12.5 | -3.9 | -24.3 | 103.6 | -5.3 | -39.8 | −39.8% |
| 2021 | 150.0 | -24.0 | -8.8 | -14.1 | -17.9 | -7.3 | -1.0 | 1.0 | -16.7 | -21.2 | -4.5 | -15.6 | −40.0% |
| 2020 | 81.1 | -28.4 | -10.4 | -9.3 | 20.5 | -11.7 | 27.7 | -11.3 | -12.8 | 2.4 | 154.8 | -15.9 | +143.2% |
| 2019 | 31.4 | -13.9 | -8.4 | -16.9 | -1.7 | -1.7 | -25.4 | -21.2 | 0.0 | -16.4 | -7.1 | -28.8 | −73.0% |
| 2018 | 5.9 | -19.2 | -1.4 | -14.4 | -3.8 | 27.0 | -25.7 | 8.3 | 0.0 | 0.0 | -13.2 | -13.3 | −46.5% |
| 2017 | 1.2 | -7.3 | 3.9 | -6.3 | -8.1 | -7.4 | -4.8 | -1.7 | 0.0 | 1.7 | 160.0 | 64.1 | +216.0% |
| 2016 | -15.2 | 39.3 | 28.2 | 16.0 | -1.7 | -14.0 | -18.4 | 0.0 | 70.0 | 82.4 | 29.0 | 1.2 | +390.9% |
| 2015 | 21.4 | 205.9 | -15.4 | -29.5 | 11.3 | -43.5 | 25.6 | -20.4 | -2.6 | 7.9 | -7.3 | -13.2 | +17.9% |
| 2014 | -33.3 | 133.3 | -42.9 | 12.5 | 11.1 | 320.0 | -26.2 | -29.0 | 63.6 | -61.1 | 57.1 | 27.3 | +211.1% |
| 2013 | — |
No analyst coverage for this instrument.
Cannabix Technologies Inc. develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) system for tetrahydrocannabinol (THC) detection and quantification, which includes the Cannabix Breath Collection Unit (BCU) and Breath Cartridge (BC) for non-invasive, portable, standardized human breath sample collection, storage, and transportation. The company also provides BreathLogix, an autonomous alcohol screening system for rapid and repeatable high-volume screening in various employment settings. In addition, the company develops other TCH-detecting technologies, including mass spectrometer breath sampler (MSBS) technology, as well as high-field asymmetric waveform ion mobility spectrometry (FAIMS) and FAIMS-mass spectrometer systems. It has a strategic partnership and development agreement with Omega Laboratories Inc. for the development and commercialization of MBT technology. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.
No recent headlines.